» Articles » PMID: 2006410

Max: a Helix-loop-helix Zipper Protein That Forms a Sequence-specific DNA-binding Complex with Myc

Overview
Journal Science
Specialty Science
Date 1991 Mar 8
PMID 2006410
Citations 667
Authors
Affiliations
Soon will be listed here.
Abstract

The myc protooncogene family has been implicated in cell proliferation, differentiation, and neoplasia, but its mechanism of function at the molecular level is unknown. The carboxyl terminus of Myc family proteins contains a basic region helix-loop-helix leucine zipper motif (bHLH-Zip), which has DNA-binding activity and has been predicted to mediate protein-protein interactions. The bHLH-Zip region of c-Myc was used to screen a complementary DNA (cDNA) expression library, and a bHLH-Zip protein, termed Max, was identified. Max specifically associated with c-Myc, N-Myc, and L-Myc proteins, but not with a number of other bHLH, bZip, or bHLH-Zip proteins. The interaction between Max and c-Myc was dependent on the integrity of the c-Myc HLH-Zip domain, but not on the basic region or other sequences outside the domain. Furthermore, the Myc-Max complex bound to DNA in a sequence-specific manner under conditions where neither Max nor Myc exhibited appreciable binding. The DNA-binding activity of the complex was dependent on both the dimerization domain and the basic region of c-Myc. These results suggest that Myc family proteins undergo a restricted set of interactions in the cell and may belong to the more general class of eukaryotic DNA-binding transcription factors.

Citing Articles

MYC in cancer: from undruggable target to clinical trials.

Whitfield J, Soucek L Nat Rev Drug Discov. 2025; .

PMID: 39972241 DOI: 10.1038/s41573-025-01143-2.


Expanding the phenotype of multiple endocrine neoplasia type 5 (MEN5): Pituitary gigantism, myelolipoma and familial pheochromocytoma due to a germline pathogenic MAX variant.

Haider A, Sundar J, Beckers A, Mohr H, Kasajima A, Pellegata N Endocrine. 2025; .

PMID: 39934510 DOI: 10.1007/s12020-025-04186-y.


Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?.

Wang W, Du Y, Datta S, Fowler J, Sang H, Albadari N Genes Dis. 2025; 12(2):101156.

PMID: 39802403 PMC: 11719324. DOI: 10.1016/j.gendis.2023.101156.


The Functional Interaction Between Epstein-Barr Virus and MYC in the Pathogenesis of Burkitt Lymphoma.

Solares S, Leon J, Garcia-Gutierrez L Cancers (Basel). 2025; 16(24.

PMID: 39766110 PMC: 11674381. DOI: 10.3390/cancers16244212.


Study of the Anti-MYC Potential of Lanostane-Type Triterpenes.

Oliveira J, Negreiro J, Nunes F, Barbosa F, Mafezoli J, Mattos M ACS Omega. 2025; 9(51):50844-50858.

PMID: 39741863 PMC: 11683602. DOI: 10.1021/acsomega.4c10201.